Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03924895




Registration number
NCT03924895
Ethics application status
Date submitted
22/04/2019
Date registered
23/04/2019
Date last updated
15/10/2024

Titles & IDs
Public title
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
Scientific title
A Randomized Phase 3 Study Evaluating Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Participants Who Are Cisplatin-Ineligible or Decline Cisplatin With Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)
Secondary ID [1] 0 0
MK-3475-905
Secondary ID [2] 0 0
3475-905
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Urinary Bladder Cancer, Muscle-invasive 0 0
Condition category
Condition code
Cancer 0 0 0 0
Bladder - transitional cell cancer
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Pembrolizumab
Treatment: Surgery - Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Treatment: Drugs - Enfortumab Vedotin

Experimental: Arm A: Pembrolizumab + Surgery - Participants receive 3 preoperative cycles of pembrolizumab, followed by standard of care surgery, followed by 14 cycles of postoperative pembrolizumab. Each cycle is 21 days.

Active comparator: Arm B: Surgery alone - Participants receive standard of care surgery alone.

Experimental: Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery - Participants receive 3 preoperative cycles of enfortumab vedotin + pembrolizumab, followed by standard of care surgery, followed by 6 cycles of postoperative enfortumab vedotin + pembrolizumab, followed by 8 cycles of pembrolizumab alone. Each cycle is 21 days.


Treatment: Drugs: Pembrolizumab
Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Treatment: Surgery: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.

Treatment: Drugs: Enfortumab Vedotin
Enfortumab vedotin 1.25 mg/kg by intravenous (IV) infusion, given on Days 1 and 8 of each 21-day cycle.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Treatment: Surgery
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Event-Free Survival (EFS) between Arm C and Arm B
Timepoint [1] 0 0
Up to approximately 6.75 years
Secondary outcome [1] 0 0
EFS between Arm A and Arm B
Timepoint [1] 0 0
Up to approximately 6.75 years
Secondary outcome [2] 0 0
Overall Survival (OS) between Arm C and Arm B
Timepoint [2] 0 0
Up to approximately 7.6 years
Secondary outcome [3] 0 0
OS between Arm A and Arm B
Timepoint [3] 0 0
Up to approximately 7.6 years
Secondary outcome [4] 0 0
Pathologic Complete Response (pCR) Rate between Arm C and Arm B
Timepoint [4] 0 0
Up to approximately 5.7 years
Secondary outcome [5] 0 0
pCR Rate between Arm A and Arm B
Timepoint [5] 0 0
Up to approximately 5.7 years
Secondary outcome [6] 0 0
Disease-Free Survival (DFS)
Timepoint [6] 0 0
Up to approximately 6.75 years
Secondary outcome [7] 0 0
Pathologic Downstaging (pDS) Rate between Arm A and Arm B
Timepoint [7] 0 0
Up to approximately 5.7 years
Secondary outcome [8] 0 0
pDS Rate between Arm C and Arm B
Timepoint [8] 0 0
Up to approximately 5.7 years
Secondary outcome [9] 0 0
Number of Participants Experiencing Adverse Events (AEs)
Timepoint [9] 0 0
Up to approximately 7.6 years
Secondary outcome [10] 0 0
Number of Participants Discontinuing Study Drug Due to Adverse Events (AEs)
Timepoint [10] 0 0
Up to approximately 1 year
Secondary outcome [11] 0 0
Number of Participants Experiencing Perioperative Complications
Timepoint [11] 0 0
Up to approximately 1 year

Eligibility
Key inclusion criteria
* Have a histologically confirmed diagnosis of urothelial carcinoma/muscle-invasive bladder cancer [MIBC] (cT2-T4aN0M0 or T1-T4aN1M0) with predominant (=50%) urothelial histology to be confirmed by Blinded Independent Central Review (BICR) (central pathology and/or imaging).
* Clinically nonmetastatic bladder cancer determined by imaging
* Eligible for radical cystectomy (RC) + pelvic lymph node dissection (PLND), and agreement to undergo curative intent standard RC + PLND (including prostatectomy if applicable)
* Ineligible for treatment with cisplatin, as defined by meeting at least one of the following criteria OR be eligible for treatment with cisplatin but decline treatment with cisplatin-based chemotherapy:

* Impaired renal function with measured or calculated creatinine clearance (CrCl) 30 to 59 mL/min (calculated by Cockcroft-Gault method, Modification of Diet of Renal Disease [MDRD] equations, or measured by 24-hour urine collection)
* Eastern Cooperative Oncology Group (ECOG) Performance Status 2
* Common Terminology Criteria for Adverse Events (CTCAE) v.4 Grade =2 audiometric hearing loss
* New York Heart Association (NYHA) Class III heart failure
* Transurethral resection (TUR) of a bladder tumor that is submitted for central pathology assessment and adequate to determine urothelial histology and PD-L1 expression assessment
* ECOG performance status of 0, 1, or 2
* Adequate organ function
* A male participant is eligible to participate if he agrees to use contraception and refrain from donating sperm during the intervention period and for at least 180 days after the last dose of enfortumab vedotin. If the male participants are receiving pembrolizumab only or undergoing surgery only, there are no contraception requirements
* A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a (woman of childbearing potential) WOCBP or a WOCBP who agrees to use a highly effective contraceptive method or be abstinent from heterosexual intercourse (as their preferred and usual lifestyle) during the intervention period and for at least 120 days after the last dose of pembrolizumab and at least 180 days after the last dose of enfortumab vedotin; whichever comes last. A female participant must agree not to donate eggs during this period as well
* A WOCBP must have a negative highly sensitive pregnancy test within 24 hours before the first dose of study intervention
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Known additional nonurothelial malignancy that is progressing or has required active anticancer treatment =3 years of study randomization, with certain exceptions
* Has = N2 or metastatic disease (M1) as identified by imaging
* Received any prior systemic treatment, chemoradiation, and/or radiation therapy for muscle-invasive bladder cancer (MIBC) or non-muscle invasive bladder cancer (NMIBC)
* Received prior therapy with an anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), or anti-programmed cell death 1 ligand 2 (PD-L2), or with an agent directed to another stimulatory or coinhibitory T-cell receptor
* Received prior systemic anticancer therapy including investigational agents within 3 years prior to randomization
* Received any prior radiotherapy to the bladder
* Received a partial cystectomy of the bladder to remove any non-muscle-invasive bladder cancer (NMIBC) or MIBC
* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
* Current participation in or participation in a study of an investigational agent or use of an investigational device within 4 weeks prior to the first dose of study intervention
* Ongoing sensory or motor neuropathy Grade 2 or higher
* Diagnosis of immunodeficiency or receipt of chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug. Physiologic replacement doses of corticosteroids are permitted for participants with adrenal insufficiency.
* Hypersensitivity to monoclonal antibodies (including pembrolizumab) and/or any of their excipients
* Severe hypersensitivity (= Grade 3) to enfortumab vedotin or any excipient contained in the drug formulation of enfortumab vedotin
* Active keratitis or corneal ulcerations. Participants with superficial punctate keratitis are allowed if the disorder is being adequately treated in the opinion of the investigator
* Active autoimmune disease that has required systemic therapy in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic therapy and is allowed
* Has uncontrolled diabetes
* History of (noninfectious) pneumonitis that required steroids, or current pneumonitis
* Active infection requiring systemic therapy
* Has had an allogeneic tissue/solid organ transplant

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
24/07/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
15/12/2027
Actual
Sample size
Target
Accrual to date
Final
595
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Western Sydney Local Health District ( Site 1259) - Blacktown
Recruitment hospital [2] 0 0
Macquarie University ( Site 1251) - Macquarie Park
Recruitment hospital [3] 0 0
Cairns Base Hospital ( Site 1257) - Cairns
Recruitment hospital [4] 0 0
Mater Misericordiae Ltd ( Site 1258) - South Brisbane
Recruitment hospital [5] 0 0
Eastern Health ( Site 1255) - Box Hill
Recruitment hospital [6] 0 0
Monash Health ( Site 1260) - Clayton
Recruitment postcode(s) [1] 0 0
2148 - Blacktown
Recruitment postcode(s) [2] 0 0
2109 - Macquarie Park
Recruitment postcode(s) [3] 0 0
4870 - Cairns
Recruitment postcode(s) [4] 0 0
4101 - South Brisbane
Recruitment postcode(s) [5] 0 0
3128 - Box Hill
Recruitment postcode(s) [6] 0 0
3168 - Clayton
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maine
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
New Jersey
Country [16] 0 0
United States of America
State/province [16] 0 0
New Mexico
Country [17] 0 0
United States of America
State/province [17] 0 0
New York
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Oklahoma
Country [20] 0 0
United States of America
State/province [20] 0 0
Oregon
Country [21] 0 0
United States of America
State/province [21] 0 0
Pennsylvania
Country [22] 0 0
United States of America
State/province [22] 0 0
South Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Virginia
Country [26] 0 0
United States of America
State/province [26] 0 0
West Virginia
Country [27] 0 0
Argentina
State/province [27] 0 0
Caba
Country [28] 0 0
Belgium
State/province [28] 0 0
Bruxelles-Capitale, Region De
Country [29] 0 0
Belgium
State/province [29] 0 0
Namur
Country [30] 0 0
Belgium
State/province [30] 0 0
Oost-Vlaanderen
Country [31] 0 0
Belgium
State/province [31] 0 0
Vlaams-Brabant
Country [32] 0 0
Belgium
State/province [32] 0 0
West-Vlaanderen
Country [33] 0 0
Canada
State/province [33] 0 0
Alberta
Country [34] 0 0
Canada
State/province [34] 0 0
British Columbia
Country [35] 0 0
Canada
State/province [35] 0 0
New Brunswick
Country [36] 0 0
Canada
State/province [36] 0 0
Ontario
Country [37] 0 0
Canada
State/province [37] 0 0
Quebec
Country [38] 0 0
Colombia
State/province [38] 0 0
Antioquia
Country [39] 0 0
Colombia
State/province [39] 0 0
Cordoba
Country [40] 0 0
Colombia
State/province [40] 0 0
Distrito Capital De Bogota
Country [41] 0 0
Colombia
State/province [41] 0 0
Santander
Country [42] 0 0
Colombia
State/province [42] 0 0
Valle Del Cauca
Country [43] 0 0
Denmark
State/province [43] 0 0
Hovedstaden
Country [44] 0 0
Denmark
State/province [44] 0 0
Midtjylland
Country [45] 0 0
Denmark
State/province [45] 0 0
Syddanmark
Country [46] 0 0
France
State/province [46] 0 0
Bouches-du-Rhone
Country [47] 0 0
France
State/province [47] 0 0
Calvados
Country [48] 0 0
France
State/province [48] 0 0
Cote-d Or
Country [49] 0 0
France
State/province [49] 0 0
Doubs
Country [50] 0 0
France
State/province [50] 0 0
Gard
Country [51] 0 0
France
State/province [51] 0 0
Gironde
Country [52] 0 0
France
State/province [52] 0 0
Haute-Garonne
Country [53] 0 0
France
State/province [53] 0 0
Ille-et-Vilaine
Country [54] 0 0
France
State/province [54] 0 0
Languedoc-Roussillon
Country [55] 0 0
France
State/province [55] 0 0
Loire-Atlantique
Country [56] 0 0
France
State/province [56] 0 0
Moselle
Country [57] 0 0
France
State/province [57] 0 0
Rhone
Country [58] 0 0
France
State/province [58] 0 0
Val-de-Marne
Country [59] 0 0
France
State/province [59] 0 0
Paris
Country [60] 0 0
Germany
State/province [60] 0 0
Baden-Wurttemberg
Country [61] 0 0
Germany
State/province [61] 0 0
Bayern
Country [62] 0 0
Germany
State/province [62] 0 0
Nordrhein-Westfalen
Country [63] 0 0
Germany
State/province [63] 0 0
Sachsen-Anhalt
Country [64] 0 0
Germany
State/province [64] 0 0
Sachsen
Country [65] 0 0
Germany
State/province [65] 0 0
Thuringen
Country [66] 0 0
Germany
State/province [66] 0 0
Berlin
Country [67] 0 0
Germany
State/province [67] 0 0
Hamburg
Country [68] 0 0
Hungary
State/province [68] 0 0
Csongrad
Country [69] 0 0
Hungary
State/province [69] 0 0
Budapest
Country [70] 0 0
Hungary
State/province [70] 0 0
Debrecen
Country [71] 0 0
Hungary
State/province [71] 0 0
Gyor
Country [72] 0 0
Hungary
State/province [72] 0 0
Kaposvar
Country [73] 0 0
Ireland
State/province [73] 0 0
Dublin
Country [74] 0 0
Ireland
State/province [74] 0 0
Waterford
Country [75] 0 0
Israel
State/province [75] 0 0
Afula
Country [76] 0 0
Israel
State/province [76] 0 0
Beer Sheva
Country [77] 0 0
Israel
State/province [77] 0 0
Haifa
Country [78] 0 0
Israel
State/province [78] 0 0
Jerusalem
Country [79] 0 0
Israel
State/province [79] 0 0
Kfar Saba
Country [80] 0 0
Israel
State/province [80] 0 0
Petach Tikva
Country [81] 0 0
Israel
State/province [81] 0 0
Ramat Gan
Country [82] 0 0
Israel
State/province [82] 0 0
Tel Aviv
Country [83] 0 0
Israel
State/province [83] 0 0
Zerifin
Country [84] 0 0
Italy
State/province [84] 0 0
Abruzzo
Country [85] 0 0
Italy
State/province [85] 0 0
Lombardia
Country [86] 0 0
Italy
State/province [86] 0 0
Piemonte
Country [87] 0 0
Italy
State/province [87] 0 0
Veneto
Country [88] 0 0
Italy
State/province [88] 0 0
Arezzo
Country [89] 0 0
Italy
State/province [89] 0 0
Catania
Country [90] 0 0
Italy
State/province [90] 0 0
Milano
Country [91] 0 0
Italy
State/province [91] 0 0
Napoli
Country [92] 0 0
Italy
State/province [92] 0 0
Pavia
Country [93] 0 0
Italy
State/province [93] 0 0
Terni
Country [94] 0 0
Japan
State/province [94] 0 0
Chiba
Country [95] 0 0
Japan
State/province [95] 0 0
Ibaraki
Country [96] 0 0
Japan
State/province [96] 0 0
Kanagawa
Country [97] 0 0
Japan
State/province [97] 0 0
Miyagi
Country [98] 0 0
Japan
State/province [98] 0 0
Nagano
Country [99] 0 0
Japan
State/province [99] 0 0
Nara
Country [100] 0 0
Japan
State/province [100] 0 0
Osaka
Country [101] 0 0
Japan
State/province [101] 0 0
Saitama
Country [102] 0 0
Japan
State/province [102] 0 0
Shizuoka
Country [103] 0 0
Japan
State/province [103] 0 0
Tokyo
Country [104] 0 0
Japan
State/province [104] 0 0
Toyama
Country [105] 0 0
Japan
State/province [105] 0 0
Gifu
Country [106] 0 0
Japan
State/province [106] 0 0
Kagoshima
Country [107] 0 0
Japan
State/province [107] 0 0
Nagasaki
Country [108] 0 0
Korea, Republic of
State/province [108] 0 0
Kyonggi-do
Country [109] 0 0
Korea, Republic of
State/province [109] 0 0
Seoul
Country [110] 0 0
Korea, Republic of
State/province [110] 0 0
Taegu-Kwangyokshi
Country [111] 0 0
Malaysia
State/province [111] 0 0
Kuala Lumpur
Country [112] 0 0
Malaysia
State/province [112] 0 0
Pulau Pinang
Country [113] 0 0
Malaysia
State/province [113] 0 0
Sarawak
Country [114] 0 0
Mexico
State/province [114] 0 0
Nuevo Leon
Country [115] 0 0
Mexico
State/province [115] 0 0
Aguascalientes
Country [116] 0 0
Mexico
State/province [116] 0 0
Chihuahua
Country [117] 0 0
Mexico
State/province [117] 0 0
Ciudad de Mexico
Country [118] 0 0
Mexico
State/province [118] 0 0
Metepec
Country [119] 0 0
Mexico
State/province [119] 0 0
Mexico City
Country [120] 0 0
Philippines
State/province [120] 0 0
Iloilo
Country [121] 0 0
Philippines
State/province [121] 0 0
National Capital Region
Country [122] 0 0
Poland
State/province [122] 0 0
Dolnoslaskie
Country [123] 0 0
Poland
State/province [123] 0 0
Kujawsko-pomorskie
Country [124] 0 0
Poland
State/province [124] 0 0
Malopolskie
Country [125] 0 0
Poland
State/province [125] 0 0
Mazowieckie
Country [126] 0 0
Poland
State/province [126] 0 0
Podlaskie
Country [127] 0 0
Poland
State/province [127] 0 0
Pomorskie
Country [128] 0 0
Poland
State/province [128] 0 0
Slaskie
Country [129] 0 0
Poland
State/province [129] 0 0
Wielkopolskie
Country [130] 0 0
Russian Federation
State/province [130] 0 0
Baskortostan, Respublika
Country [131] 0 0
Russian Federation
State/province [131] 0 0
Ivanovskaya Oblast
Country [132] 0 0
Russian Federation
State/province [132] 0 0
Krasnoyarskiy Kray
Country [133] 0 0
Russian Federation
State/province [133] 0 0
Kurskaya Oblast
Country [134] 0 0
Russian Federation
State/province [134] 0 0
Moskva
Country [135] 0 0
Russian Federation
State/province [135] 0 0
Murmanskaya Oblast
Country [136] 0 0
Russian Federation
State/province [136] 0 0
Nizhegorodskaya Oblast
Country [137] 0 0
Russian Federation
State/province [137] 0 0
Omskaya Oblast
Country [138] 0 0
Russian Federation
State/province [138] 0 0
Sankt-Peterburg
Country [139] 0 0
Russian Federation
State/province [139] 0 0
Saratovskaya Oblast
Country [140] 0 0
Russian Federation
State/province [140] 0 0
Sverdlovskaya Oblast
Country [141] 0 0
Russian Federation
State/province [141] 0 0
Tyumenskaya Oblast
Country [142] 0 0
Singapore
State/province [142] 0 0
Central Singapore
Country [143] 0 0
South Africa
State/province [143] 0 0
Gauteng
Country [144] 0 0
South Africa
State/province [144] 0 0
Western Cape
Country [145] 0 0
Spain
State/province [145] 0 0
Barcelona
Country [146] 0 0
Spain
State/province [146] 0 0
Cataluna
Country [147] 0 0
Spain
State/province [147] 0 0
Extremadura
Country [148] 0 0
Spain
State/province [148] 0 0
Gerona
Country [149] 0 0
Spain
State/province [149] 0 0
Madrid, Comunidad De
Country [150] 0 0
Spain
State/province [150] 0 0
Valenciana, Comunitat
Country [151] 0 0
Spain
State/province [151] 0 0
Madrid
Country [152] 0 0
Spain
State/province [152] 0 0
Sevilla
Country [153] 0 0
Sweden
State/province [153] 0 0
Jonkopings Lan
Country [154] 0 0
Sweden
State/province [154] 0 0
Stockholms Lan
Country [155] 0 0
Sweden
State/province [155] 0 0
Uppsala Lan
Country [156] 0 0
Sweden
State/province [156] 0 0
Vasterbottens Lan
Country [157] 0 0
Sweden
State/province [157] 0 0
Vastra Gotalands Lan
Country [158] 0 0
Thailand
State/province [158] 0 0
Krung Thep Maha Nakhon
Country [159] 0 0
Thailand
State/province [159] 0 0
Chiang Mai
Country [160] 0 0
Thailand
State/province [160] 0 0
Khon Kaen
Country [161] 0 0
Turkey
State/province [161] 0 0
Ankara
Country [162] 0 0
Turkey
State/province [162] 0 0
Istanbul
Country [163] 0 0
Turkey
State/province [163] 0 0
Konya
Country [164] 0 0
Turkey
State/province [164] 0 0
Sakarya
Country [165] 0 0
Turkey
State/province [165] 0 0
Trabzon
Country [166] 0 0
Ukraine
State/province [166] 0 0
Cherkaska Oblast
Country [167] 0 0
Ukraine
State/province [167] 0 0
Dnipropetrovska Oblast
Country [168] 0 0
Ukraine
State/province [168] 0 0
Kharkivska Oblast
Country [169] 0 0
Ukraine
State/province [169] 0 0
Khersonska Oblast
Country [170] 0 0
Ukraine
State/province [170] 0 0
Kyivska Oblast
Country [171] 0 0
Ukraine
State/province [171] 0 0
Lvivska Oblast
Country [172] 0 0
Ukraine
State/province [172] 0 0
Zhytomyrska Oblast
Country [173] 0 0
Ukraine
State/province [173] 0 0
Kyiv
Country [174] 0 0
United Kingdom
State/province [174] 0 0
England
Country [175] 0 0
United Kingdom
State/province [175] 0 0
Hertfordshire
Country [176] 0 0
United Kingdom
State/province [176] 0 0
London, City Of
Country [177] 0 0
United Kingdom
State/province [177] 0 0
Midlothian
Country [178] 0 0
United Kingdom
State/province [178] 0 0
Truro
Country [179] 0 0
United Kingdom
State/province [179] 0 0
Walsall
Country [180] 0 0
United Kingdom
State/province [180] 0 0
Wirral

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Merck Sharp & Dohme LLC
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Seagen Inc.
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/industry
Name [2] 0 0
Astellas Pharma Global Development, Inc.
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (MIBC).

The primary hypothesis is that perioperative pembrolizumab plus radical cystectomy (RC) plus pelvic lymph node dissection (PLND) and perioperative enfortumab vedotin in combination with pembrolizumab plus RC+PLND will achieve superior event-free survival (EFS) compared with RC+PLND alone.

With Amendment 5, outcome measures for programmed cell death ligand 1 (PD-L1) combined positive score (CPS) were removed.

With Amendment 8, the primary outcome measure of pathologic complete response (pCR) rates was changed to a secondary outcome measure.
Trial website
https://clinicaltrials.gov/study/NCT03924895
Trial related presentations / publications
Galsky MD, Hoimes CJ, Necchi A, Shore N, Witjes JA, Steinberg G, Bedke J, Nishiyama H, Fang X, Kataria R, Sbar E, Jia X, Siefker-Radtke A. Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncol. 2021 Aug;17(24):3137-3150. doi: 10.2217/fon-2021-0273. Epub 2021 May 19.
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Merck Sharp & Dohme LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03924895